| Expression pattern: |
UP |
| Associated gene: |
KAT6B, S100A8, S100A9, PDGF, VEGF |
| Associated microRNA: |
miR-22 |
| Biological function: |
circ_0127646 promotes cisplatin resistance in osteosarcoma cells; silencing circ_0127646 enhances cisplatin-induced apoptosis and diminishes clonogenic capacity. |
| Molecular mechanism: |
circ_0127646 acts as a ceRNA sponge of miR-22, regulates KAT6B expression, downregulates cytokines S100A8, S100A9, PDGF, and VEGF after inhibition, and prevents activation of the PI3K/Akt/mTOR pathway to sensitize osteosarcoma cells to cisplatin. |
| Biological pathway or process: |
PI3K/AKT/mTOR (promotes); apoptosis (inhibits); proliferation (promotes); autophagy (promotes); ceRNA regulation (other); chemoresistance (promotes); drug resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Bioinformatics Analysis; Transfection; CCK8; Annexin V/PI Flow Cytometry; Colony Formation Assay; Luciferase Reporter Assay; Western Blot |
| Clinical significance: |
Circ_0127646 might serve as a prognostic biomarker for cisplatin-based therapies and a potential therapeutic target in OS. |
| Description: |
circ_0127646 is up-regulated in osteosarcoma cell lines after cisplatin treatment and is associated with reduced cisplatin sensitivity. Its inhibition enhances cisplatin-induced apoptosis and suppresses clonogenic growth through the miR-22/KAT6B axis, downregulating S100A8, S100A9, PDGF, and VEGF and inhibiting PI3K/Akt/mTOR signaling. The study proposes circ_0127646 as a potential biomarker and therapeutic target for cisplatin-based treatment in osteosarcoma. |
| Confidence score: |
0.5607 |